Market Signal Briefing

The team behind the Shiba Inu cryptocurrency has teased "something new" in its recent social media post.

The new project has been described as "wallet-friendly," "useful," and "unmistakably SHIB." 

The social media account, which boasts nearly four million followers, has also tagged Bidget Wallet in its most recent social media post. 

Jaded community The community responses are clearly mixed, with SHIB holders showing visible frustration with the team.  

Some users have criticized the rather unfortunate timing of the announcement, given that the entire cryptocurrency market recently experienced a rather severe price crash. 

There are also those who are dissatisfied with slow and inefficient burns. 

The perceived lack of transparency also appears to be a major concern among SHIB naysayers. 

The price of the SHIB token is down 89.4% from its record high, according to CoinGecko data. 

The Ethereum price is showing a bottom signal as NUPL drops to 0.23, its weakest level since July, but this does not fully match the conditions that marked the last major reversal.Heavy long-liquidation pressure remains in the market, with a thick cluster sitting near $3,050, which continues to suppress any attempt at a rebound despite low profit-taking incentives.Ethereum is still trading inside a falling channel, and real strength only returns if price reclaims $3,653 and then $3,795, the levels needed to flip the structure from bearish to neutral.Ethereum price is down 18.5% in the past 30 days and about 5.2% this week. It is holding up slightly better than Bitcoin on the weekly chart, but it is nowhere close to recovery. One key on-chain signal shows that most traders have almost no reason left to book profits.

Under normal conditions, that would help form a bottom. However, if profit-taking pressure has already dissipated, the obvious question is why the Ethereum price still refuses to bounce.

Sponsored

Profit-Booking Incentive Drops, But Not Enough To Confirm A BottomNet Unrealized Profit and Loss (NUPL) has dropped to 0.23, the lowest reading since July 1. NUPL tracks investor psychology by measuring the amount of unrealized profit or loss in the market.

It shifts between phases such as capitulation, where most wallets hold losses, and belief or denial, where confidence grows.

ETH Profit-Booking Reasons Are Fewer Now: GlassnodeWant more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

The last time NUPL dropped even lower was June 22, when it hit 0.17. That move came right before Ethereum rallied 106.3%, which helped NUPL rise from capitulation into belief and denial.

Today’s reading sits above that level, which means ETH has room to fall further if the market weakens.

Sponsored

A lower NUPL print would match the conditions that existed before the previous major reversal. Although profit-taking incentives are now minimal, the bottom signal is not yet fully aligned.

Liquidation Pressure Explains Why Price Isn’t Responding To NUPLThe derivatives market gives the clearest reason for Ethereum’s hesitation. On Gate’s ETH-USDT liquidation map, short exposure is heavy at $2.36 billion, but long exposure is still sizeable at $1.05 billion.

Ethereum Liquidation Map: CoinglassSponsored

This imbalance keeps pressure on both sides. The thickest long-liquidation cluster stretches roughly to $3,050. ETH is trading near this level, which means even a mild drop can trigger forced selling from long traders.

Long Liquidation Leverage Could Limit Upside: CoinglassLong liquidations can easily overpower the positive effect of low NUPL. Even if shorts are over-exposed, the remaining long leverage is large enough to keep the market unstable.

This is the link between the two metrics: Ethereum cannot use a profit-bottom setup as long as this long-liquidation wall remains intact.

Sponsored

Ethereum Price Chart Lines Up With The Same Risk ZoneThe Ethereum price chart reinforces the same story. ETH is still trading inside a falling channel, and the $3,053 region remains the most important support. This is the exact zone where the strongest long-liquidation cluster sits. If the price loses $3,053, the odds of a deeper drop rise sharply.

That kind of drop aligns with the path where NUPL could slide toward its June low of 0.17, matching the setup that preceded the last major leg higher.

Ethereum Price Analysis: TradingViewThere is a bullish path, but it needs far bigger confirmation. ETH must reclaim $3,653 to show real strength, which is still more than 14% above current levels. From there, clearing $3,795 would flip the structure from bearish to neutral.

This move also tests the upper boundary of the falling channel, which has only two clean touches and is not a strong resistance. If NUPL stabilizes, shorts begin to unwind, and Ethereum price clears these levels, a sharp rebound becomes possible. Until those conditions merge, ETH stays trapped between a fading profit motive and a stubborn liquidation overhang.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Robert Kiyosaki stated in a post on Saturday that despite Bitcoin (CRYPTO: BTC) prices crashing, he's holding onto the cryptocurrency.

Why Kiyosaki Is Not Selling BTCKiyosaki revealed that despite the market’s current challenges, he is holding onto his assets, including Bitcoin. The "Rich Dad Poor Dad" author attributes the decline to a global cash demand but notes he does not need liquidity at this time.

"Simply said…..if you are fearful and need cash….as most of the world does…. You may want to sell your best assets and go to cash," he added.

He anticipates a scenario described in Lawrence Lepard's "The Big Print," where assets like gold, silver, Bitcoin, and Ethereum (CRYPTO: ETH) may gain value as fiat currencies depreciate.

Learning From MistakesKiyosaki noted that he has panicked many times in the past and that he has learned "priceless personal financial lessons" which are not taught in traditional schools.

"I do not trust stocks or bonds but if you do….like Warren Buffet…do what is best for you," he said.

BTC, ETH's 2025 So FarBitcoin, which was at $93,463 at the beginning of 2025, dipped below this level earlier this week before recouping some of the losses. BTC was hovering at $95,871 at the time of writing, up around 2.6% year-to-date.

Ethereum was at $3,331 at the beginning of 2025, and was hovering at $3,209 at the time of writing, down 3.7% year-to-date.

Broader Crypto DeclineThe recent plunge in Bitcoin’s value is part of a broader trend affecting cryptocurrencies. On Thursday, Bitcoin fell below the $100,000 mark, despite optimism over the end of the U.S. government shutdown. This drop coincided with heavy net outflows from spot Bitcoin ETFs, reducing the institutional buying pressure that had previously supported prices.

The BTC decline has sparked discussions about Bitcoin’s four-year halving cycle. Analysts, including Scott Melker, have noted that the cycle, which typically sees market peaks 12-18 months post-halving, may be weakening. The market is now over 1,080 days past the last low, yet the anticipated euphoria phase has not materialized.

Economist Peter Schiff also weighed in, challenging Bitcoin supporters with a poll asking how low Bitcoin must fall before they concede he was “right” all along.

Read Next:

What A $90,000 Bitcoin Dip Would Mean For Ethereum, XRP
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo courtesy: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The chip maker blew the AI trade wide open in the spring of 2023. It might need to do it again.

Shares fell by over 11% after the company released its Q3 2025 earnings report. Selling has not let up.

Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation

November 16, 2025 01:02 ET

 | Source:

Waldencast plc

NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD), today announced new data shared at the recent American Society for Dermatologic Surgery (ASDS) Annual Meeting, which took place November 13–16, 2025, in Chicago, Illinois.

Pivotal FDA Study Comparison of Two Hyaluronic Acid Fillers for Midface Augmentation and Associated Improvement in Nasolabial Folds Appearance led to Obagi Hyaluronic Acid Featured as a Top 10 Abstract Presented by Dr. Sue Ellen Cox:

“As an investigator in this pivotal study, I was pleased that the data was recognized as one of the top 10 abstracts and selected for an oral presentation,” commented Dr. Sue Ellen Cox. “The data highlights the compelling results of the Obagi® saypha® ChIQ™ pivotal study and shows the potential of the product to provide high-level satisfaction for patients seeking long-lasting, natural-looking results.”

This pivotal, randomized, multicenter trial compared the effectiveness and safety of two hyaluronic acid fillers for midface volume restoration and nasolabial fold improvement. The study demonstrated non-inferiority of Obagi® saypha® ChIQ™ ** compared to Juvéderm Voluma® XC, with high patient satisfaction and robust safety across diverse skin types.

Additional Abstracts:

Obagi Scalp Serum Interim 3 Month Results

Interim data from the ongoing study of Obagi Nu-Cil® BioStim™ Scalp Serum highlights improvements in scalp health and hair appearance at three months.

A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies

This research introduces a novel framework for evaluating HA fillers and showcases category-leading capabilities of the Obagi line of injectables.

"Obagi Medical’s commitment to advancing dermatologic science and driving innovation is reflected in the data shared across our skincare and injectable portfolio at the recent ASDS meeting," said Drew Fine, U.S. General Manager, Professional Channel. "New products with proven quality, a well-established safety profile, and high patient satisfaction are critical to expanding the aesthetic injectable market. The selection of the Obagi® saypha® ChIQ™ abstract as one of the top 10 for oral presentation highlights the powerful data supporting the new Obagi injectable."

Nu-Cil® BioStim™ Scalp Serum expands on Obagi’s 35 years of skin health expertise and leadership in medical-grade innovation by applying its skin-first philosophy to the scalp through the BioStim™ Complex. The BioStim™ Complex utilizes proprietary technology powered by a synergistic blend of clinically proven actives, including biotin, amino acids, and peptides—alongside 18 essential nutrients, B vitamins, and phytoactives. These actives work to promote scalp health, fortify hair follicles, and strengthen strands from the root.

Obagi® saypha® ChIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology that creates a stable 3D HA matrix designed to provide natural-looking results with category-leading capabilities, including high HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile. Obagi® saypha® ChIQ™ is currently under review for FDA approval. Obagi Medical’s Obagi® saypha® MagIQ™ was recently FDA approved.

About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,* Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi is available on the brand’s website, https://www.obagi.com.

*Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
** Obagi® saypha® ChIQ™ is currently under review for FDA approval

About Waldencast
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the business combination with Obagi Medical and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com/. 

About Croma-Pharma GmbH 
Founded in 1976, Croma-Pharma GmbH is a family-owned global player in the field of minimally invasive aesthetic medicine. Headquartered in Leobendorf, Austria, the company specializes in the industrial production of hyaluronic acid syringes and distributes its products in more than 80 countries. Croma offers a comprehensive aesthetics portfolio including HA fillers, botulinum toxin, PDO threads, and biostimulators. Saypha(R) is a registered trademark of Croma-Pharma GmbH, used under license. Learn more at www.croma.at. 

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the planned launch of Saypha® MagIQ™, the ability to obtain FDA approval for Saypha®, and the growth strategies of Waldencast, including Obagi Medical and Novaestiq. These forward-looking statements generally are identified by the words “estimates,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “would,” “should,” “future,” “propose,” “target,” “goal,” “objective,” “outlook” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of Waldencast, Obagi Medical and Novaestiq that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, but are not limited to: (i) the inability to obtain FDA approval for Saypha® ChIQ products, (ii) the success of any commercial launches, (iii) the general impact of geopolitical events, including the impact of current wars, conflicts and other hostilities, (iv) the overall economic and market conditions, sales forecasts and other information about Waldencast’s possible or assumed future results of operations or our performance, (v) changes in general economic conditions, (vi) the impact of any international trade or foreign exchange restrictions, the imposition of new or increased tariffs, foreign currency exchange fluctuations, (vii) that the price of Waldencast’s securities may be volatile due to a variety of factors, including Waldencast’s, Obagi Medical’s or Novaestiq’s inability to implement their business plans, and (viii) the ability to implement Waldencast’s strategic initiatives and continue to innovate Obagi Medical’s existing products and anticipate and respond to market trends and changes in consumer preferences. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Waldencast’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on March 20, 2025, or in other documents that may be filed or furnished by Waldencast from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Waldencast assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts

Investors
ICR
[email protected]

Media
ICR
[email protected]

2 mins mins

Key Points:

Brown and Emory University increased Bitcoin ETF holdings dramatically.Over $65 million Bitcoin investment by two universities.Increased institutional participation in digital assets markets.
On September 30, Brown and Emory Universities disclosed substantial Bitcoin ETF holdings, with Brown holding $13.8 million of IBIT and Emory amassing $51.82 million in Grayscale Bitcoin Trust.

These investments signify increased institutional adoption of Bitcoin, underscoring its growing acceptance within higher education endowments and potentially influencing broader market dynamics.

Universities Allocate $65 Million in Bitcoin ETFs
Brown University allocated approximately $13.8 million to BlackRock’s iShares Bitcoin Trust (IBIT), while Emory University increased its position in Grayscale Bitcoin Trust to over $51.82 million and added 4,450 IBIT shares, reflecting a strong institutional inclination toward cryptocurrency-based investments.

The universities’ enhanced Bitcoin engagement suggests increasing confidence in digital assets as viable investment vehicles. Emory University’s CIO, Srinivas Pulavarti, stated:

“There are some risks with doing it yourself. Whereas if you use a company like Grayscale or BlackRock to do it for you… it’s unlikely that they’re going to steal your money because they’re well known.”Market analysts, like Bloomberg’s Eric Balchunas, emphasize that such high-profile institutional involvement in Bitcoin ETFs indicates a significant step toward wider acceptance across traditional financial sectors. He described it as a “watershed moment” for institutional adoption, potentially boosting market credibility.

Analysts Forecast Market Impact and Regulatory Changes
Did you know? Institutional interest from prominent universities, like Emory and Brown, in Bitcoin ETFs mirrors prior financial organizations’ ventures into digital assets, marking a broader acceptance baseline not seen before 2025.

According to CoinMarketCap, Bitcoin (BTC) currently trades at $95,157.12, with a market cap of $1.90 trillion and maintaining a dominance of 58.72%. Its 24-hour trading volume is down by 69.27% to $34.77 billion. Over the last three months, BTC’s price has decreased by 18.93%.

Bitcoin(BTC), daily chart, screenshot on CoinMarketCap at 01:06 UTC on November 16, 2025. Source: CoinMarketCap

Experts from Coincu suggest this institutional involvement could create a more robust framework for Bitcoin in conventional finance, possibly stabilizing its price volatility. They anticipate further regulatory developments as educational institutions enhance their presence in the cryptocurrency sector.

DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.

Rate this post

3 mins mins

Key Points:

Balancer hackers laundered 2,000 ETH through Tornado Cash.The action raises security concerns in the DeFi sector.Regulatory scrutiny on DeFi protocols is likely to increase.
On November 15, Balancer hackers laundered 2,000 ETH worth $6.36 million through Tornado Cash, effectively ending any possibility of asset return or white-hat negotiations.

This action escalates security risks for Balancer and conflicts with regulatory scrutiny on DeFi laundering pathways.

DeFi Security Concerns Escalate Amidst Regulatory Scrutiny
Tornado Cash laundering marks a critical phase in the Balancer exploit. On-chain analyst Yu Jin noted, “After exchanging ETH LST tokens and other non-ETH tokens for ETH, the Balancer hackers began laundering and transferring ETH through Tornado: in the past hour, they deposited 2,000 ETH ($6.36 million) into Tornado” – PANews. This activity highlights advanced methods used in obfuscating illicit gains.

Market observers note that the abandonment of white-hat alternatives and the ongoing laundering strategy have raised concerns over asset recovery and compliance monitoring. These actions could further erode trust in Balancer and similar DeFi platforms.

Community reactions are mixed, with some demanding enhanced security measures across the sector. On-chain analysts such as

see the Tornado Cash usage as a significant laundering phase initiation. There is no immediate reaction from major industry figures, though regulatory bodies continue to observe DeFi activities closely. Regulatory bodies continue to observe DeFi activities closely.

Market Data and Expert Insights
Did you know? Laundering assets through Tornado Cash follows a pattern established by prior high-profile DeFi hacks, reducing chances of recovery. Historically, few assets routed through such mixers are returned.

CoinMarketCap reports Ethereum (ETH) currently priced at $3,175.66, with a market cap of $383.29 billion and a 24-hour trading volume of $19.15 billion, decreasing by 57.72%. In the past 90 days, ETH has declined by 27.18%, amidst wider market fluctuations.

Ethereum(ETH), daily chart, screenshot on CoinMarketCap at 02:36 UTC on November 16, 2025. Source: CoinMarketCap

Industry experts indicate that the hacker activity could precipitate greater scrutiny of DeFi protocols by regulatory authorities. Analysts from the Coincu research team suggest that a robust framework for smart contract auditing will likely become standard practice, given the repeated incidents involving obscured fund transfers. This suggestion from the Coincu research team suggests that a robust framework for smart contract auditing will likely become standard practice, given the repeated incidents involving obscured fund transfers.

DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.

Rate this post

The recent decline in Bitcoin has sparked a new wave of debate across the crypto market. After prices briefly dipped below $95,000, many traders began circulating the idea that Bitcoin has already reached its cycle bottom.

Avenir Group has strengthened its position as one of the most influential Bitcoin investors in Asia, raising its holdings in BlackRock's iShares Bitcoin Trust (IBIT) to more than $1.18 billion. The company disclosed the updated numbers in its latest SEC filing, reflecting a new milestone in its approach to digital asset adoption.

XRP’s sharp reversal came despite the anticipated launch of 21Shares, Bitwise, CoinShares, and Franklin Templeton XRP-spot ETFs in the week ahead.

Canary XRP ETF Trading Volume Drops amid Crypto Market Turmoil
XRPC impressed on day one of trading, with $59 million in trading volume and net inflows of $245 million. However, volumes dropped to $26 million on Friday, November 14, weighing on the appetite for XRP on Saturday, November 15.

The broader crypto market sell-off and BTC-spot ETF outflows likely influenced institutional demand.

However, demand for XRP could soar in the week ahead, given the launch of Bitwise and Franklin Templeton’s XRP-spot ETFs.

Franklin Templeton is the largest ETF issuer launching a spot ETF, with assets under management of $43.16 billion. The ETF is expected to launch on Tuesday, November 18. Meanwhile, Bitwise has $5.7 billion in AUM, also dwarfing Canary Capital’s $71.2 million in AUM. The Bitwise XRP ETF is slated to launch between November 19 and 20.

Analysts expect Franklin Templeton and Bitwise to dominate the XRP-spot ETF market, given the absence of a BlackRock (BLK) iShares XRP Trust. Robust inflows could trigger a reversal of recent losses, potentially sending XRP toward $3.

US Economic Data and the Fed in the Spotlight
The timing of XRP-spot ETF launches is everything. Fading bets on a December Fed rate cut and rising stagflation risks could dampen initial demand for XRP through ETFs.

In the week ahead, crucial US inflation and jobs data will influence risk assets. Rising consumer prices and a deteriorating labor market could weigh on demand for risk assets, such as XRP and XRP-spot ETFs.

FOMC members have recently raised concerns about elevated inflation, lowering bets on a December rate cut. According to the CME FedWatch Tool, the chances of a rate cut dropped from 66.9% on Friday, November 7, to 44.4% on Friday, November 14.

With key US economic reports in focus, traders should closely monitor FOMC member speeches. Reactions to the incoming data and views on monetary policy are likely to influence sentiment.

Technical Outlook: Key XRP Price Levels
XRP fell 0.40% on Saturday, November 15, following the previous day’s 3.37% loss, closing at $2.2354. The token underperformed the broader crypto market, which rose 1.12%.

Five consecutive days of losses left XRP trading well below the 50-day and 200-day Exponential Moving Averages (EMAs), indicating bearish momentum.

Looking ahead, several scenarios could trigger a trend reversal, potentially sending XRP toward $3.

Key technical levels to watch include:

Support levels: $2.2, $2.0, and $1.9.
50-day EMA resistance: $2.5089.
200-day EMA resistance: $2.5687.
Resistance levels: $2.35, $2.5, $2.62, $2.8, $3.0, and $3.66.

SummaryBlackstone Secured Lending is upgraded to a 'buy' due to its attractive valuation and defensive first-lien debt portfolio.BXSL's net investment income and yield are under pressure from falling interest rates, but even in light of a slight dividend cut, the yield would still be attractive.BXSL boasts industry-leading non-accrual ratios and improved portfolio company fundamentals, supporting its resilience despite a challenging credit environment.With BXSL now trading at a slight discount to NAV and offering an 11.6% yield, the risk/reward profile is compelling, despite ongoing rate risks. bunhill/E+ via Getty Images

Blackstone Secured Lending Fund (BXSL) has been one of my go-to BDCs for quite some time, given its highly defensive portfolio proven by top-tier metrics across the industry. I've been navigating between "buy" and "hold" ratings regarding BXSL depending on its stock price, and my last

Analyst’s Disclosure:I/we have a beneficial long position in the shares of BXSL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The information, opinions, and thoughts included in this article do not constitute an investment recommendation or any form of investment advice.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Dividend stocks can strengthen your portfolio during any market environment.

As an investor, you imagine your portfolio increasing in value as your stocks climb -- and this could happen. But there's an additional way to gain in the stock market, and this particular investing strategy will bring you guaranteed returns year after year. I'm talking about buying dividend stocks.

These companies offer you a payout regardless of what the market -- or even the dividend-paying stock -- is doing, so you can count on them for passive income. This is a way to protect your portfolio during difficult times and supercharge growth in stronger environments. So, by investing in these players, you're setting yourself up for victory during any market phase.

Now, the big question is: How should you choose a dividend stock? After all, some companies may offer a payment this year, but then turn around and suspend their dividend the following year. Of course, no one can guarantee what a company will do, but you can be reasonably optimistic that a certain group of players will continue not only paying but increasing their dividends year after year. These are known as Dividend Kings. Let's check out two of these sweet dividend leaders to buy to satisfy your craving for passive income.

Image source: Getty Images.

1. Coca-Cola
Coca-Cola (KO +0.13%) doesn't need much of an introduction, thanks to its famous drink. But the company's business doesn't stop there. It encompasses a wide variety of products, from water and juices to coffee and tea brands. This entire portfolio, led by its flagship sparkling beverages line, has helped Coca-Cola become a household name and grow steadily over time.

An example of the company's strength: Coca-Cola calls today's environment "challenging" but still managed to increase revenue and earnings per share by 5% and 6%, respectively, in the recent quarter. This is thanks to the company's solid moat, including its franchise business model and brand strength, as well as Coca-Cola's focus on adapting its beverages to local markets.

Today's Change

(

0.13

%) $

0.09

Current Price

$

71.16

Meanwhile, the company boasts a fantastic record of dividend growth, having increased its payments for 63 consecutive years. This shows a commitment to rewarding shareholders, suggesting the company will continue along this path. Today, Coca-Cola pays a dividend of $2.04, representing a dividend yield of 2.8%, surpassing that of the S&P 500.

KO Dividend Yield data by YCharts.

All this makes Coca-Cola a buy for its great business and for its commitment to sharing the wealth with investors.

2. Abbott Laboratories
I particularly like Abbott Laboratories (ABT +1.03%) for two big reasons: The company is well diversified across the healthcare industry, and it's known for several leading products. We'll talk about diversification first, and this has to do with Abbott's business model. The company has four units: Medical devices, nutrition, diagnostics, and established pharmaceuticals. This scope means that if one unit faces headwinds, another may compensate. That limits risk for the company and for investors.

Today's Change

(

1.03

%) $

1.33

Current Price

$

130.59

Second, Abbott is known for some pretty significant products, from the FreeStyle Libre continuous glucose monitoring (CGM) system for diabetes to the MitraClip minimally invasive treatment for heart valve repair. Abbott is also the maker of popular nutrition brands such as Ensure. These are delivering growth -- for example, CGM revenue soared 20% in the recent quarter to $2 billion -- and Abbott's commitment to innovation should keep the momentum growing.

On top of this wonderful healthcare business, Abbott, like Coca-Cola, has made rewarding shareholders part of its strategy. The company has increased its dividend for 53 straight years, and the dividend today has reached the level of $2.36, reflecting a dividend yield of 1.8%. Like Coca-Cola, Abbott offers a higher yield than that of the S&P 500.

All this makes Abbott a great choice for investors craving passive income -- and a company that has what it takes to deliver steady growth over the long term.

HD Hyundai Chairman Chung Kisun meets Admiral Daryl Caudle, U.S. Chief of Naval Operations, to discuss MASGA cooperation
Admiral boarded the newly launched second Aegis Destroyer ROKS Dasan Jeong Yak-yong and toured the construction site of the third vessel
, /PRNewswire/ -- Admiral Daryl Caudle, Chief of Naval Operations of the United States, visited HD Hyundai Heavy Industries to witness the company's world-class shipbuilding capabilities and discuss cooperation under the MASGA (Make America Shipbuilding Great Again) initiative.

HD Hyundai Chairman Chung Kisun poses for a commemorative photo with Admiral Daryl Caudle, U.S. Chief of Naval Operations, during his visit to HD Hyundai Heavy Industries’ Ulsan shipyard on Saturday, November 15, 2025.

HD Hyundai Chairman Chung Kisun and Admiral Daryl Caudle, U.S. Chief of Naval Operations, board the newly launched ROKS Dasan Jeong Yak-yong, the second Aegis destroyer, at HD Hyundai Heavy Industries’ Ulsan shipyard on Saturday, November 15, 2025. After inspecting the ship’s interior, they pose for a commemorative photo.

HD Hyundai Heavy Industries recently announced that Adm. Caudle and Kevin Kim, Chargé d'Affaires of the U.S. Embassy in Korea, along with their delegation, visited its Ulsan headquarters on Saturday, November 15. During the visit, HD Hyundai Chairman Chung Kisun met with Adm. Caudle in person to introduce HD Hyundai's advanced shipbuilding technologies and competitiveness, and to exchange views on future collaboration through the Korea–U.S. shipbuilding cooperation project, MASGA.

At the meeting, Chairman Chung and Adm. Caudle discussed ways to strengthen bilateral cooperation aimed at improving the operational readiness of the U.S. Navy fleet through strategic partnerships in naval shipbuilding.

After the meeting, Chairman Chung guided Adm. Caudle on a tour of HD Hyundai Heavy Industries' commercial shipbuilding facilities, followed by a visit to the company's Naval Ship Division, where the world's most advanced Aegis destroyers are built.

Adm. Caudle boarded the newly launched ROKS Dasan Jeong Yak-yong, the second Aegis destroyer constructed by HD Hyundai Heavy Industries, and received a briefing from the commanding officer on the ship's state-of-the-art combat systems and operational capabilities. He also observed the construction of the third Aegis destroyer, scheduled for launch next year, and inspected production lines for other various naval vessels.

HD Hyundai Heavy Industries is currently integrating its naval, commercial, and mid-sized shipbuilding capabilities through a merger with HD Hyundai Mipo, restructuring its operations to maximize synergy across the shipbuilding sector. Based on this integration, the company aims to expand exports and defense cooperation projects in global markets, including the United States.

With naval forces around the world modernizing their fleets, demand for next-generation destroyers and frigates is steadily rising. Leveraging its proven track record in building advanced Aegis destroyers and delivering naval vessels for foreign clients such as the Philippine Navy and the Peruvian Navy, HD Hyundai Heavy Industries is actively expanding its presence in major global defense markets, including the United States.

Adm. Caudle's visit is expected to further advance discussions on technical cooperation and supply chain integration in the warship construction domain between HD Hyundai and the U.S. Navy.

Chairman Chung shared, "HD Hyundai will support the growth of the U.S. shipbuilding industry and to strengthen the U.S. Navy's capabilities. As blood allies and close friends, we will work together to ensure the success of the MASGA, the shipbuilding cooperation project between Korea and the U.S."

Likewise, HD Hyundai is broadening its cooperation with the U.S. Navy across multiple domains. In April, John Phelan, Secretary of the US Navy, visited HD Hyundai Heavy Industries and boarded the ROKS Jeongjo the Great, the first vessel of the next-generation Aegis destroyer class. The previous month, Chairman Chung visited the United States Naval Academy in Annapolis, Maryland — the cradle of the world's most powerful navy — where he met with faculty members and cadets to exchange views on future directions and research opportunities in the maritime field.

SOURCE HD Hyundai

NEWTOWN, Pa. , Nov. 15, 2025  /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Coty Inc. (NYSE: COTY), resulting from allegations of providing potentially misleading business information to the investing public.

November 15, 2025 9:10 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 15, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (2) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of Jasper's products, including briquilimab; (3) the foregoing increased the likelihood of disruptive cost-reduction measures; (4) accordingly, Jasper's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274682

November 15, 2025 10:00 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 15, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of KBR, Inc. (NYSE: KBR) between May 6, 2025 and June 19, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased KBR securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the KBR class action, go to https://rosenlegal.com/submit-form/?case_id=42136 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) despite the knowledge that the U.S. Department of Defense's Transportation Command (TRANSCOM) had, for months, had material concerns with HomeSafe's ability to fulfill the Global Household Goods Contract, defendants claimed that the partnership was without issue, and would ramp up in future quarters; and (2) as a result, defendants' statements about KBR's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the KBR class action, go to https://rosenlegal.com/submit-form/?case_id=42136 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274537

November 15, 2025 10:12 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 15, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS" or "ADSs") of WPP plc (NYSE: WPP) between February 27, 2025 and July 8, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline.

SO WHAT: If you purchased WPP ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the WPP class action, go to https://rosenlegal.com/submit-form/?case_id=46121 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of WPP's media arm; notably, that it was not truly equipped to handle the ongoing macroeconomic challenges while competing effectively and had instead begun to lose significant market share to its competitors. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the WPP class action, go to https://rosenlegal.com/submit-form/?case_id=46121 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274683

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

3 hours ago

Steak 'n Shake, an American fast food restaurant company, first began accepting BTC in May and is now expanding its stores to El Salvador.

952

Steak ‘n Shake, a fast food restaurant company in the United States that accepts Bitcoin (BTC), announced on Saturday that it is expanding into El Salvador.

“We were honored to be in Bitcoin Country,” the company said in an X post following Steak ‘n Shake's participation in the country’s Bitcoin Histórico event on Wednesday and Thursday.

Steak ‘n Shake started accepting BTC for payment at its stores in May, and the company’s chief operations officer, Dan Edwards, told Cointelegraph that the goal is to have BTC accepted at all of the company’s locations worldwide.

Source: Steak ‘n ShakeThe company attributed a nearly 11% rise in same-store sales in Q2 to its decision to start accepting BTC at its restaurants.

The company has become iconic in the Bitcoin community and highlights the growing number of merchants accepting BTC for goods and services. Acceptance of BTC as tender for small, everyday purchases is also a precursor to mass adoption.

Steak ‘n Shake backtracks on accepting Ether as a payment method and celebrates Q3 sales Steak ‘n Shake polled its followers on the X social media platform in October, asking whether it should accept Ether (ETH) as payment at its locations.

53% of the 48,815 followers polled voted in favor of the proposal, sparking significant backlash from the Bitcoin community.

“ETH is centralized garbage. Bitcoin is freedom. Doing this would lose you all your Bitcoiner business, including mine,” Bitcoin maximalist Ron Sovereignty Swanson said in response.

Although initially promising to “abide by the results” of the social media poll, Steak ‘n Shake backtracked on the proposal to accept ETH.

“Poll suspended. Our allegiance is with Bitcoiners. You have spoken. Who even allowed this? I'm back at my desk,” the company said on October 11 — the same day the poll was initiated.

Steak ‘n Shake leads the competition in same-store sales increase in Q3. Source: Steak ‘n ShakeIn November, the company celebrated strong Q3 sales, touting a 15% quarter-over-quarter increase in same-store sales.

Steak ‘n Shake managed to lead all other competitors in the fast food category for same-store sales increases in Q3, including McDonald's, Burger King, Taco Bell, and coffeehouse Starbucks.

Magazine: Big Questions: Did a time-traveling AI invent Bitcoin?

MicroStrategy's position in Bitcoin has once again become a major conversation point in the crypto market, not because of its usual high-profile accumulation, but due to rumors of a massive sell-off. As Bitcoin slid below $95,000 — its lowest level in more than a month — speculation surged across social media that Michael Saylor's company had liquidated over $1 billion worth of BTC.

The market downturn has done little to slow down developer activity in the real-world asset (RWA) sector, where leading blockchain projects continue to build infrastructure for institutional and enterprise adoption. According to new data from Santiment, Chainlink has expanded its lead as the most active network for development within the tokenization landscape, even while prices across the broader crypto market remain under pressure.

Journalist

Posted: November 16, 2025

Key Takeaways
What’s driving Zcash’s recent surge in price and market cap?
Anticipation of shielded ZEC purchases via Zashi Wallet has sparked aggressive buying across spot and Futures markets.

 What price levels are critical for ZEC’s next move?
ZEC must break above $750 to target $875, or it may find support near $495 if momentum fades.

Since hitting a low of $423, Zcash [ZEC] has closed at higher highs for three consecutive days. As a result, the altcoin held above both its short-term and long-term Moving Averages. 

In fact, at press time, Zcash was trading at $673, up 30.72% on daily charts. This price uptick was backed by an 82% jump in trading volume.

Equally, its market cap has jumped by 35%, making it the 12th-largest cryptocurrency. But what’s behind this upsurge?

Shielded Zcash purchases trigger speculation
Despite broader crypto market volatility, the Zcash market has remained optimistic, largely due to the upcoming launch of shielded transactions on the Zashi Wallet.

Starting next week, users will be able to privately swap other cryptocurrencies into shielded ZEC via Zashi Wallet, a feature powered by Near Intents and highly anticipated by the community.

With this feature, investors can swap their coins, such as Bitcoin [BTC], into shielded ZEC at the same nominal value. While the feature has received praise from many in the market, it has also drawn sharp criticism from ZachXBT.

 The on-chain monitor warned of potential leakage from using Zcash transparent addresses for refunds. 

Buyers stage a strong comeback
Zcash recorded three consecutive days of positive Buy Sell Delta. Over the past 24 hours, the altcoin saw 1.6 million in Buy Volume compared to 1.4 million in Sell Volume. 

Source: Coinalyze

As a result, the altcoin recorded a positive Buy Sell Delta of 200K, a clear sign of aggressive spot accumulation. 

Futures are even more aggressive.
After the market signaled recovery, investors rushed into the futures market to strategically position themselves. 

In fact, buyers have dominated the futures market over the past week, as evidenced by Futures Taker CVD. This metric has remained green throughout the past week, signaling buyer dominance. 

Source: CryptoQuant

Coupled with that, Derivatives Volume surged 104.92% to $9.4 billion, while Open Interest jumped 43.93% to $1.28 billion, at press time. When these metrics rise together, it indicates increased participation and capital inflows into futures. 

Meanwhile, the Long Short Ratio rose to 1.04, suggesting that most of these buyers entered the market to take long positions. 

Source: CoinGlass

As such, most participants are bullish and anticipate prices to rise further in the near term.

What’s next for ZEC?
Zcash bounced back amid soaring speculation over the upcoming shielded ZEC purchases next week. Riding in this wave, the altcoin’s demand recovered across the spot and futures markets.

As a result, the altcoin’s Stochastic Momentum Index (SMI) made a bullish crossover, rising to 6.6, indicating strong upward momentum.

Source: TradingView

When this metric crosses over, it usually indicates growing buyer dominance and potential for higher prices. If demand remains strong, ZEC could break through the $750 resistance and target $875.

However, if the breakout fails, ZEC is likely to find support near $495, where the 18-day moving average currently sits.

In a tumultuous second week of November, the global cryptocurrency market saw a staggering $280 billion wiped off its total valuation, plunging the market cap to approximately $3.3 trillion. This decline was characterized by Bitcoin slipping below the psychological $100,000 mark for the second week in a row, marking its lowest price in six months.